Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints rare diseases research head

Birgitte Volck moves to the company from Swedish Ophan Biovitrum

GSK Sobi Birgitte VolckGlaxoSmithKline has appointed Birgitte Volck has its new head of rare diseases R&D.

She will join GSK after working her six months notice at Swedish Ophan Biovitrum (Sobi), which she joined four years ago and where she served as its chief medical officer.

Sobi's president and CEO Geoffrey McDonough said: "We thank Birgitte for her leadership and dedication which has helped to evolve Sobi's patient oriented research and development organisation into a highly skilled international team.

"Birgitte joined Sobi in 2012 and has been instrumental in advancing Sobi's late stage development projects and in bringing new treatment options to people with rare diseases."

Prior to joining Stockholm-based Sobi Volck spent five years at Amgen, where she served as executive development director, bone, neuroscience and inflammation, international R&D.

Before Amgen she held positions with Genzyme as Nordic medical director and project director and at Denmark's Pharmexa as vice president, clinical development and medical affairs.

15th January 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...

Infographics